Castrate-resistant prostate cancer response to taxane is determined by an HNF1-dependent apoptosis resistance circuit

Metastatic castrate-resistant prostate cancer (mCRPC) is a genetically and phenotypically heterogeneous cancer where advancements are needed in biomarker discovery and targeted therapy. A critical and often effective component of treatment includes taxanes. We perform a high-throughput screen across...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell reports. Medicine 2024-12, Vol.5 (12), p.101868, Article 101868
Hauptverfasser:	Senatorov, Ilya S., Bowman, Joel, Jansson, Keith H., Alilin, Aian Neil, Capaldo, Brian J., Lake, Ross, Riba, Morgan, Abbey, Yasmine C., Mcknight, Crystal, Zhang, Xiaohu, Raj, Sonam, Beshiri, Michael L., Shinn, Paul, Nguyen, Holly, Thomas, Craig J., Corey, Eva, Kelly, Kathleen
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals apoptosis Apoptosis - drug effects Baculoviral IAP Repeat-Containing 3 Protein - genetics Baculoviral IAP Repeat-Containing 3 Protein - metabolism BIRC3 Bridged-Ring Compounds - pharmacology Bridged-Ring Compounds - therapeutic use Cell Line, Tumor docetaxel Docetaxel - pharmacology Docetaxel - therapeutic use drug resistance Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics Gene Expression Regulation, Neoplastic - drug effects Hepatocyte Nuclear Factor 1-alpha - genetics Hepatocyte Nuclear Factor 1-alpha - metabolism HNF1A Humans Male organoid Organoids - drug effects Organoids - metabolism Organoids - pathology pharmacology prostate cancer Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - genetics Prostatic Neoplasms, Castration-Resistant - metabolism Prostatic Neoplasms, Castration-Resistant - pathology Taxoids - pharmacology Taxoids - therapeutic use xenograft
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!